FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1371-1373 March 31, 2005 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Stallone, G. PubMed Citation

Improvements in immunosuppressive therapy during the past decade have brought us closer to the day when long-term acceptance of organ allografts will be routine. These achievements, however, have run up against an important limitation: death of the recipient from cardiovascular disease, infection, and cancer.¹ As compared with an age-matched healthy population or with patients undergoing dialysis, organ-transplant recipients have an increased incidence of cancer; one study found that after 20 years of immunosuppressive therapy, 40 percent of recipients had cancer.² Further burdens are to be expected in an aging population of transplant recipients with well-functioning allografts.

The causes of the . . . [Full Text of this Article]

Source Information

From the Institut de Transplantation et de Recherche en Transplantation, INSERM Unité 463, Nantes University, Centre Hospitalier Régional Universitaire de Nantes, Nantes, France.

This article has been cited by other articles:

• Elazary, R., Schlager, A., Appelbaum, L., Zamir, G., Nir, I. (2009). Renal clear cell carcinoma emerging in a transplanted kidney 3 years after return to dialysis. Case report and review of the literature. NDT Plus 2: 476-478 [Abstract] [Full Text]  
• Hui, R. L, Lide, W., Chan, J., Schottinger, J., Yoshinaga, M., Millares, M. (2009). Association Between Exposure to Topical Tacrolimus or Pimecrolimus and Cancers. The Annals of Pharmacotherapy 43: 1956-1963 [Abstract] [Full Text]  
• Bresson, D., von Herrath, M. (2009). Immunotherapy for the Prevention and Treatment of Type 1 Diabetes: Optimizing the path from bench to bedside. Diabetes Care 32: 1753-1768 [Full Text]  
• Mudge, G. H. Jr (2007). Sirolimus and Cardiac Transplantation: Is It the "Magic Bullet"?. Circulation 116: 2666-2668 [Full Text]  
• Gerrits, J. H., van de Wetering, J., Postma, S., Drabbels, J. J. M., Vaessen, L. M. B., IJzermans, J. N. M., Rischen, J., Claas, F. H. J., Weimar, W., van Besouw, N. M. (2007). Stable T-cell reactivity after successful tapering of azathioprine in HLA-identical living-related kidney transplant recipients despite minor histocompatibility antigen mismatches. Nephrol Dial Transplant 22: 353-361 [Abstract] [Full Text]  
• Djamali, A., Samaniego, M., Muth, B., Muehrer, R., Hofmann, R. M., Pirsch, J., Howard, A., Mourad, G., Becker, B. N. (2006). Medical Care of Kidney Transplant Recipients after the First Posttransplant Year. CJASN 1: 623-640 [Abstract] [Full Text]